Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan 1;22(1):3-10.
doi: 10.31557/APJCP.2021.22.1.3.

Prognostic Value of Two Polymorphisms, rs1045642 and rs1128503, in ABCB1 Following Taxane-based Chemotherapy: A Meta-Analysis

Quanyao Chen  1 , Wanlong Lin  1 , Jianhui Yang  1 , Min Lin  1 , Xiuxian Lin  1 , Yiyin Weng  1 , Yao Chen  1
Affiliations
Review

Prognostic Value of Two Polymorphisms, rs1045642 and rs1128503, in ABCB1 Following Taxane-based Chemotherapy: A Meta-Analysis

Quanyao Chen et al. Asian Pac J Cancer Prev. .

Abstract

Objective: Genetic polymorphisms can influence the chemotherapeutic response; however, previous studies have produced conflicting results, and have failed to identify the most relevant polymorphisms for predicting the response to treatment in patients with cancer. The present meta-analysis was conducted to determine the correlation between two polymorphisms (rs1045642 and rs1128503) in ATP-binding cassette transporter B subfamily member 1 (ABCB1), which is associated with multidrug resistance, and the survival of patients treated with taxane-containing chemotherapy.

Methods: Several databases, including PubMed and Embase, were used to retrieve articles evaluating the association between the ABCB1 rs1045642 and rs1128503 polymorphisms and survival, published prior to August 2019. The meta-analysis was conducted using R software to determine the pooled hazard ratio (HR) and 95% confidence intervals (95% CIs).

Results: Fifteen studies involving 3320 patients were included in the meta-analysis. The effect of the rs1128503 polymorphism on progression-free survival remained significant in the heterozygote (HR 0.81; 95% CI: 0.67-0.98) and homozygote (HR 0.71; 95% CI: 0.58-0.88) models. The TT genotype rs1128503 was associated with better overall survival (HR 0.72; 95% CI: 0.53-0.97).

Conclusion: Carriers of the rs1128503 T allele of ABCB1 showed a survival benefit after taxane-containing chemotherapy.

Keywords: ABCB1; Overall survival; Paclitaxel; Progression-free survival; taxane.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow Diagram of the Literature Search and Trial Selection Process
Figure 2
Figure 2
Forest Plots of ABCB1 rs1045642 Polymorphism and Subgroup Analyses on Progression-Free Survival of Patients Administered Taxane-Based Chemotherapy
Figure 3
Figure 3
Forest Plots of ABCB1 rs1045642 Polymorphism and Subgroup Analyses for Overall Survival of Patients Administered Taxane-Based Chemotherapy
Figure 4
Figure 4
Forest Plots of ABCB1 rs1128503 Polymorphism and Subgroup Analyses for Progression-Free Survival and Overall Survival of Patients Administered Taxane-Based Chemotherapy
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Auner V, Sehouli J, Oskay-Oezcelik G, et al. ABC transporter gene expression in benign and malignant ovarian tissue. Gynecol Oncol. 2010;117:198–201. - PubMed
    1. Bergmann TK, Green H, Brasch-Andersen C, et al. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol. 2011;67:693–700. - PubMed
    1. Bjorn N, Jakobsen Falk I. ABCB1 variation affects myelosuppression, progression-free survival and overall survival in paclitaxel/carboplatin-treated ovarian cancer. Patients. 2018;123:277–87. - PubMed
    1. Bosch TM, Huitema AD, Doodeman VD, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel. Clin Cancer Res. 2006;12:5786–93. - PubMed
    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. - PubMed